203. 22q11.2欠失症候群 22q11.2 deletion syndrome Clinical trials / Disease details
臨床試験数 : 5 / 薬物数 : 7 - (DrugBank : 1) / 標的遺伝子数 : 14 - 標的パスウェイ数 : 23
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT04639960 (ClinicalTrials.gov) | September 29, 2017 | 3/11/2020 | Neuroprotective Effects of Risperdal on Brain and Cognition in 22q11 Deletion Syndrome | Effects of Modulation of the Dopaminergic System Using Risperidone on Memory and Executive Processes in Individuals With 22q11.2 Deletion Syndrome | 22q11.2 Deletion Syndrome | Drug: Risperdal;Drug: Placebo | University of Geneva, Switzerland | NULL | Terminated | 11 Years | 25 Years | All | 16 | N/A | Switzerland |